

Kwee L Yong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5500283/publications.pdf>

Version: 2024-02-01

237
papers

8,183
citations

76031

42
h-index

62345

84
g-index

238
all docs

238
docs citations

238
times ranked

9067
citing authors

#	ARTICLE	IF	CITATIONS
1	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: <scp>IKEMA</scp> subgroup analysis. American Journal of Hematology, 2023, 98, .	2.0	6
2	Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial. British Journal of Haematology, 2022, 196, .	1.2	0
3	Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression. British Journal of Haematology, 2022, 196, .	1.2	3
4	Comparative Efficacy of Ciltacabtagene Autoleucl in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Clinical Drug Investigation, 2022, 42, 29-41.	1.1	16
5	Adaptation of the PERCEPT myeloma prehabilitation trial to virtual delivery: changes in response to the COVID-19 pandemic. BMJ Open, 2022, 12, e059516.	0.8	3
6	Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study. Thrombosis Research, 2022, 213, 27-29.	0.8	8
7	Comparative effectiveness of ciltacabtagene autoleucl in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. EJHaem, 2022, 3, 97-108.	0.4	13
8	Myeloma patients' experiences of a supervised physical activity programme: a qualitative study. Supportive Care in Cancer, 2022, 30, 6273-6286.	1.0	6
9	Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2854-2864.	3.2	6
10	Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination. Leukemia and Lymphoma, 2022, , 1-5.	0.6	0
11	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematological Oncology, 2022, 40, 1020-1029.	0.8	6
12	The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study. Supportive Care in Cancer, 2022, 30, 7469-7479.	1.0	2
13	Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nature Communications, 2022, 13, .	5.8	11
14	Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 160-162.	0.6	2
15	COVID-19 and myeloma clinical research " experience from the CARDAMON clinical trial. British Journal of Haematology, 2021, 192, e14-e16.	1.2	7
16	DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. British Journal of Haematology, 2021, 192, e73-e77.	1.2	3
17	Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. British Journal of Haematology, 2021, 192, 997-1005.	1.2	6
18	Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set. Leukemia and Lymphoma, 2021, 62, 1243-1246.	0.6	5

#	ARTICLE	IF	CITATIONS
19	How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. <i>Clinical Hematology International</i> , 2021, 3, 27.	0.7	1
20	Multiple myeloma. <i>Lancet, The</i> , 2021, 397, 410-427.	6.3	349
21	Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 618610.	2.2	7
22	A rare case of relapsed multiple myeloma with aberrant Tâ€cell antigen expression and skin plasmacytomas. <i>EJHaem</i> , 2021, 2, 301-302.	0.4	0
23	Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. <i>British Journal of Haematology</i> , 2021, 193, e19-e22.	1.2	3
24	Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. <i>British Journal of Haematology</i> , 2021, 193, 750-760.	1.2	8
25	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021, 22, e105-e118.	5.1	136
26	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>). <i>Haematologica</i> , 2021, 106, 2694-2706.	1.7	6
27	BCMA CARs in multiple myeloma: room for more?. <i>Blood</i> , 2021, 137, 2859-2860.	0.6	1
28	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8026-8026.	0.8	5
29	Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8000-8000.	0.8	5
30	Multiple myeloma and physical activity. <i>BMC Research Notes</i> , 2021, 14, 171.	0.6	9
31	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8034-8034.	0.8	1
32	Subgroup analysis of ICARIAâ€MM study in relapsed/refractory multiple myeloma patients with highâ€risk cytogenetics. <i>British Journal of Haematology</i> , 2021, 194, 120-131.	1.2	27
33	Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8042-8042.	0.8	5
34	Physical Activity During and After Haematological Cancer Treatment: A Cross-Sectional Survey of Haematology Healthcare Professionals in the United Kingdom. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 1659-1671.	1.1	6
35	Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 3023-3026.	0.6	1
36	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet, The</i> , 2021, 397, 2361-2371.	6.3	177

#	ARTICLE	IF	CITATIONS
37	Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 703233.	1.3	6
38	Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy. <i>British Journal of Haematology</i> , 2021, 194, 857-861.	1.2	3
39	Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience. <i>Leukemia and Lymphoma</i> , 2021, , 1-4.	0.6	0
40	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. <i>Future Oncology</i> , 2021, 17, 4797-4812.	1.1	6
41	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021, 35, 562-572.	3.3	43
42	Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors. <i>British Journal of Haematology</i> , 2021, 196, e21.	1.2	11
43	OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KcD) consolidation for newly diagnosed (NDTE) multiple myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S2-S3.	0.2	1
44	Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes. <i>Blood</i> , 2021, 138, 723-723.	0.6	0
45	Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KcD) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk. <i>Blood</i> , 2021, 138, 2911-2911.	0.6	0
46	Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients. <i>Blood</i> , 2021, 138, 458-458.	0.6	1
47	Autophagy Blockade Disrupts Myeloma Cell Recovery from Proteasome Inhibition and Enhances Apoptosis. <i>Blood</i> , 2021, 138, 1567-1567.	0.6	0
48	Daratumumab, Bortezomib and Dexamethasone (DvD) at First Relapse for Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A UK Myeloma Research Alliance (UK-MRA) Real-World Multicentre Analysis. <i>Blood</i> , 2021, 138, 4120-4120.	0.6	3
49	Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors. <i>Blood</i> , 2021, 138, 1628-1628.	0.6	0
50	A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2676-2676.	0.6	1
51	Autologous Haematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia: A Single-Centre 18-Year Experience. <i>Blood</i> , 2021, 138, 3548-3548.	0.6	1
52	Co-Operation of MCL-1 and BCL-X L Anti-Apoptotic Proteins in Stromal Protection of MM Cells from Carfilzomib Mediated Cytotoxicity. <i>Blood</i> , 2021, 138, 2677-2677.	0.6	0
53	P-039: Adaptation of a myeloma minimal residual disease multi-parametric flow assay for real world practice. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S59-S60.	0.2	0
54	OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S30.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. <i>Future Oncology</i> , 2020, 16, 4347-4358.	1.1	60
56	Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. <i>British Journal of Haematology</i> , 2020, 191, 194-206.	1.2	58
57	A real-world study of panobinostat, weekly bortezomib and dexamethasone in a very heavily pretreated population of multiple myeloma patients. <i>British Journal of Haematology</i> , 2020, 191, 927-930.	1.2	5
58	Response to - Impact of immunosuppression on mortality in critically ill COVID-19 patients™. <i>British Journal of Haematology</i> , 2020, 191, 505-506.	1.2	0
59	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. <i>Blood</i> , 2020, 136, 3033-3040.	0.6	146
60	Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design. <i>British Journal of Cancer</i> , 2020, 123, 187-195.	2.9	35
61	Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 200-205.	1.4	12
62	Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations. <i>British Journal of Haematology</i> , 2020, 190, e312-e316.	1.2	3
63	Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light chain amyloidosis. <i>British Journal of Haematology</i> , 2020, 189, 643-649.	1.2	25
64	Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. <i>Haematologica</i> , 2020, 105, e261-e263.	1.7	40
65	PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma. <i>BMJ Open</i> , 2020, 10, e033176.	0.8	15
66	Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4+PD-1+ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 3443-3454.	3.2	33
67	The adapted Zelen was a feasible design to trial exercise in myeloma survivors. <i>Journal of Clinical Epidemiology</i> , 2020, 125, 76-83.	2.4	5
68	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	0.8	110
69	Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-70.	0.9	0
70	Levofloxacin prophylaxis in patients with myeloma - Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e69.	5.1	0
71	Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (<sc>MUK</sc> six open label, multi-centre phase I<sc>II</sc> Clinical Trial). <i>British Journal of Haematology</i> , 2019, 185, 573-578.	1.2	8
72	A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on <sc>ISS</sc> and <sc>PFS</sc>1. <i>British Journal of Haematology</i> , 2019, 185, 350-353.	1.2	2

#	ARTICLE	IF	CITATIONS
73	Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. <i>British Journal of Haematology</i> , 2019, 187, 638-641.	1.2	35
74	Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. <i>Journal of Bone Oncology</i> , 2019, 17, 100243.	1.0	15
75	Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1760-1772.	5.1	109
76	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 2096-2107.	6.3	435
77	Understanding mortality in multiple myeloma: Findings of a European retrospective chart review. <i>European Journal of Haematology</i> , 2019, 103, 107-115.	1.1	23
78	Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1617-1628.	0.8	24
79	The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from <sc>BSBMT</sc>/<sc>UKMF</sc> Myeloma X) Tj ETQq1 1 0.784314 rgB 14 450-467.	1.2	33
80	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	1.2	33
81	Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?. <i>Haematologica</i> , 2019, 104, 2128-2131.	1.7	3
82	Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis – a first report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e309.	0.2	1
83	Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e5-e6.	0.2	1
84	Comparison of PET Reconstruction Algorithms on Assessment and Quantification of FDG-PETCT Findings in Patients with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e171.	0.2	0
85	Oral proteasome inhibitor maintenance for multiple myeloma. <i>Lancet</i> , The, 2019, 393, 204-205.	6.3	4
86	Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. <i>British Journal of Haematology</i> , 2019, 185, 981-984.	1.2	18
87	Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse. <i>British Journal of Haematology</i> , 2019, 185, 948-951.	1.2	3
88	Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres. <i>British Journal of Haematology</i> , 2019, 186, 162-165.	1.2	2
89	Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 3112-3112.	0.6	38
90	Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study. <i>Blood</i> , 2019, 134, 861-861.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-94.	1.3	3
92	Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide. <i>Blood</i> , 2019, 134, 4340-4340.	0.6	0
93	Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome. <i>Blood</i> , 2019, 134, 4368-4368.	0.6	0
94	The start of a new wave: Developments in proteasome inhibition in multiple myeloma. <i>European Journal of Haematology</i> , 2018, 101, 220-236.	1.1	15
95	An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. <i>Blood</i> , 2018, 131, 746-758.	0.6	131
96	Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. <i>Journal of Medical Economics</i> , 2018, 21, 450-467.	1.0	15
97	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology</i> , 2018, 19, 1641-1653.	5.1	193
98	Deferred autologous stem cell transplantation in systemic AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 101.	2.8	28
99	RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. <i>Blood</i> , 2018, 132, 2154-2165.	0.6	14
100	National survey of imaging practice for suspected or confirmed plasma cell malignancies. <i>British Journal of Radiology</i> , 2018, 91, 20180462.	1.0	5
101	Raised VEGF. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e486.	3.1	24
102	More convenient proteasome inhibition for improved outcomes. <i>Lancet Oncology</i> , 2018, 19, 856-858.	5.1	3
103	The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. <i>Trials</i> , 2018, 19, 169.	0.7	8
104	Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. <i>Blood</i> , 2018, 132, 255-255.	0.6	4
105	Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease. <i>Blood</i> , 2018, 132, 802-802.	0.6	6
106	Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study. <i>Blood</i> , 2018, 132, 306-306.	0.6	3
107	Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma. <i>Blood</i> , 2018, 132, 3255-3255.	0.6	0
108	Encouraging Outcomes for Patients with Multiple Myeloma Treated in Early Phase Clinical Trials: A Single Centre and Meta-Analysis. <i>Blood</i> , 2018, 132, 5663-5663.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Fatigue, Quality of Life, and Physical Fitness Following an Exercise Intervention in Survivors of Multiple Myeloma: A Randomised Controlled Trial Using a Zelen Design. <i>Blood</i> , 2018, 132, 974-974.	0.6	0
110	Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. <i>British Journal of Haematology</i> , 2017, 176, 888-907.	1.2	44
111	Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. <i>British Journal of Haematology</i> , 2017, 176, 908-917.	1.2	25
112	Real World Data of the Impact of first cycle Daratumumab on Multiple Myeloma and Amyloidosis Services. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e157.	0.2	0
113	Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction. <i>European Radiology</i> , 2017, 27, 5325-5336.	2.3	62
114	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. <i>Hematological Oncology</i> , 2017, 35, 432-439.	0.8	8
115	Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. <i>British Journal of Haematology</i> , 2017, 176, 222-233.	1.2	48
116	Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse. <i>British Journal of Haematology</i> , 2017, 177, 495-497.	1.2	0
117	Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159. <i>Blood</i> , 2017, 130, 741-741.	0.6	33
118	Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 MUK Five Study. <i>Blood</i> , 2017, 130, 835-835.	0.6	6
119	Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients. <i>Blood</i> , 2017, 130, 903-903.	0.6	20
120	Multiple myeloma: practice patterns across Europe. <i>British Journal of Haematology</i> , 2016, 175, 66-76.	1.2	91
121	17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management. <i>Hematological Oncology</i> , 2016, 34, 165-170.	0.8	3
122	Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. <i>British Journal of Haematology</i> , 2016, 174, 911-922.	1.2	122
123	Cyclin D type does not influence cell cycle response to DNA damage caused by ionizing radiation in multiple myeloma tumours. <i>British Journal of Haematology</i> , 2016, 173, 693-704.	1.2	5
124	Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. <i>Lancet Haematology</i> , 2016, 3, e572-e580.	2.2	39
125	Advances in understanding prognosis in myeloma. <i>British Journal of Haematology</i> , 2016, 175, 367-380.	1.2	27
126	Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing. <i>BMC Cancer</i> , 2016, 16, 444.	1.1	19

#	ARTICLE	IF	CITATIONS
127	The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2016, 3, e340-e351.	2.2	120
128	Global hypomethylation in myeloma is associated with poor prognosis. <i>British Journal of Haematology</i> , 2016, 172, 473-475.	1.2	21
129	Multiple myeloma: patient outcomes in real-world practice. <i>British Journal of Haematology</i> , 2016, 175, 252-264.	1.2	220
130	Myeloma impairs mature osteoblast function but causes early expansion of osteoprogenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. <i>British Journal of Haematology</i> , 2016, 172, 64-79.	1.2	17
131	The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. <i>BMC Hematology</i> , 2016, 16, 14.	2.6	7
132	Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1926-1937.	2.0	16
133	Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1009-1016.	2.0	8
134	Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. <i>British Journal of Cancer</i> , 2016, 114, 7-13.	2.9	30
135	POEMS Syndrome: Demographics and Outcomes in a United Kingdom Cohort. <i>Blood</i> , 2016, 128, 5582-5582.	0.6	0
136	Cohort analysis of FISH testing of CD138 ⁺ cells in relapsed multiple myeloma: implications for prognosis and choice of therapy. <i>British Journal of Haematology</i> , 2015, 171, 881-883.	1.2	8
137	Multiple myeloma and physical activity: a scoping review. <i>BMJ Open</i> , 2015, 5, e009576.	0.8	40
138	Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUK1 randomized dose selection trial. <i>British Journal of Haematology</i> , 2015, 170, 336-348.	1.2	19
139	Time to redefine Myeloma. <i>British Journal of Haematology</i> , 2015, 171, 1-10.	1.2	18
140	RAS mutation status and bortezomib therapy for relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2015, 169, 905-908.	1.2	18
141	An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2015, 168, 148-151.	1.2	4
142	Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. <i>Annals of Hematology</i> , 2015, 94, 643-649.	0.8	13
143	Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience. <i>Blood</i> , 2015, 126, 3180-3180.	0.6	0
144	The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation <i>in vitro</i> : defining the stromal defect in myeloma. <i>British Journal of Haematology</i> , 2014, 167, 194-206.	1.2	15

#	ARTICLE	IF	CITATIONS
145	Myeloma presenting during pregnancy. <i>Hematological Oncology</i> , 2014, 32, 52-55.	0.8	8
146	Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. <i>Leukemia and Lymphoma</i> , 2014, 55, 1661-1662.	0.6	14
147	Updates to the guidelines for the diagnosis and management of multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 131-133.	1.2	20
148	High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 15, 874-885.	8.1	139
149	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	5.1	695
150	Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. <i>Blood</i> , 2014, 123, 2513-2517.	0.6	32
151	Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC). <i>Blood</i> , 2014, 124, 4745-4745.	0.6	1
152	The Effects of CAMPATH-1H on Cell Viability Do Not Correlate to the CD52 Density on the Cell Surface. <i>PLoS ONE</i> , 2014, 9, e103254.	1.1	8
153	A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. <i>BMC Cancer</i> , 2013, 13, 31.	1.1	52
154	Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. <i>Supportive Care in Cancer</i> , 2013, 21, 599-607.	1.0	48
155	Multiple myeloma. <i>BMJ</i> , The, 2013, 346, f3863-f3863.	3.0	64
156	Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial. <i>British Journal of Haematology</i> , 2013, 163, 541-543.	1.2	4
157	Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma. <i>European Journal of Haematology</i> , 2013, 90, 420-425.	1.1	11
158	A Second Autologous Stem Cell Transplant (ASCT2) Induces Superior Durability Of Response (DuR) Following Bortezomib-Containing Re-Induction Therapy For Relapsed Multiple Myeloma (MM): Final Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial. <i>Blood</i> , 2013, 122, 765-765.	0.6	1
159	Engraftment defect of cytokine-cultured adult human mobilized CD34+ cells is related to reduced adhesion to bone marrow niche elements. <i>British Journal of Haematology</i> , 2012, 158, 778-787.	1.2	27
160	Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. <i>Leukemia</i> , 2012, 26, 1761-1770.	3.3	20
161	Reinfused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma. <i>British Journal of Haematology</i> , 2012, 157, 494-496.	1.2	2
162	Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma. <i>British Journal of Haematology</i> , 2012, 158, 499-505.	1.2	6

#	ARTICLE	IF	CITATIONS
163	Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma. PLoS ONE, 2012, 7, e41127.	1.1	28
164	Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4+ α fCD45RA+ α fCD27 α T cells: the potential involvement of interleukin-7 in this process. Immunology, 2011, 132, 326-339.	2.0	85
165	APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood, 2011, 117, 890-901.	0.6	50
166	Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 2011, 154, 32-75.	1.2	252
167	Relapsed multiple myeloma in the UK prior to the introduction of novel agents - a response to Koleva et al. (2010). European Journal of Cancer Care, 2011, 20, 697-699.	0.7	0
168	CD26 Inhibition Can Aid the Homing of Cytokine Activated Mobilized Peripheral Blood (MPB)CD34+ Cells to the Bone Marrow (BM) but a Ligand Dependent Attachment Defect Prevents Their Long Term Retention and Subsequent Engraftment. Blood, 2011, 118, 141-141.	0.6	1
169	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,. Blood, 2011, 118, 3976-3976.	0.6	12
170	An Alternate Day Dosing Strategy for Lenalidomide in Multiple Myeloma Improves Cost-Effectiveness Whilst Maintaining Efficacy,. Blood, 2011, 118, 4201-4201.	0.6	0
171	Bortezomib α induced inflammatory neuropathy. Journal of the Peripheral Nervous System, 2010, 15, 366-368.	1.4	32
172	CD20 α positive multiple myeloma α differential expression of cyclins D1 and D2 suggests a heterogeneous disease. British Journal of Haematology, 2010, 149, 156-159.	1.2	11
173	Different Proliferative Potential and Migratory Characteristics of Human CD4+ Regulatory T Cells That Express either CD45RA or CD45RO. Journal of Immunology, 2010, 184, 4317-4326.	0.4	205
174	An unusual case of myocardial infarction. BMJ Case Reports, 2010, 2010, bcr1120092422-bcr1120092422.	0.2	0
175	The Effect of Myeloma Cells on Bone Homeostasis Is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo. Blood, 2010, 116, 4052-4052.	0.6	0
176	Multiple myeloma presenting with spinal cord compression during pregnancy. Annals of Hematology, 2009, 88, 181-182.	0.8	25
177	Proliferative Effect of APRIL On Primary Multiple Myeloma Cells Is Dictated by D-Type Cyclin Group and Translocation Status.. Blood, 2009, 114, 124-124.	0.6	0
178	Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model. Haematologica, 2008, 93, 1457-1465.	1.7	113
179	Outcomes in Relapsed Multiple Myeloma in the UK: A Retrospective Observational Study. Blood, 2008, 112, 4689-4689.	0.6	0
180	Dendritic cells and myeloid leukaemias: plasticity and commitment in cell differentiation. British Journal of Haematology, 2007, 138, 281-290.	1.2	20

#	ARTICLE	IF	CITATIONS
181	Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells. <i>British Journal of Haematology</i> , 2007, 139, 243-254.	1.2	15
182	An Exercise Training Programme Produces Significant Improvements in Quality of Life (QoL), Muscle Strength and Cardiorespiratory Function in Patients with Myeloma.. <i>Blood</i> , 2007, 110, 3323-3323.	0.6	0
183	Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. <i>Journal of Gene Medicine</i> , 2006, 8, 253-264.	1.4	49
184	663. Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Reverse Osteoclast Activation in a Xenogeneic Murine Model of Multiple Myeloma. <i>Molecular Therapy</i> , 2006, 13, S256.	3.7	1
185	Factors Influencing Short Term In Vivo Biodistribution of Human Bone Marrow Derived Mesenchymal Stem Cells (hMSCs) in a Xenogeneic Animal Model.. <i>Blood</i> , 2006, 108, 3182-3182.	0.6	0
186	Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.. <i>Blood</i> , 2006, 108, 505-505.	0.6	0
187	Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. <i>British Journal of Haematology</i> , 2005, 129, 763-770.	1.2	112
188	Differential expression of CD180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. <i>British Journal of Haematology</i> , 2005, 131, 313-319.	1.2	28
189	Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24. <i>Clinical Cancer Research</i> , 2005, 11, 3377-3384.	3.2	31
190	Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects. <i>British Journal of Haematology</i> , 2004, 125, 756-765.	1.2	14
191	Maturation of DC is associated with changes in motile characteristics and adherence. <i>Cytoskeleton</i> , 2004, 57, 118-132.	4.4	137
192	Evaluation of the Taguchi methods for the simultaneous assessment of the effects of multiple variables in the tumour microenvironment. <i>International Seminars in Surgical Oncology</i> , 2004, 1, 7.	1.1	7
193	Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 186-194.	2.0	93
194	Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. <i>Blood</i> , 2004, 103, 1548-1556.	0.6	193
195	Impaired bone marrow homing of cytokine-activated CD34+ cells in the NOD/SCID model. <i>Blood</i> , 2004, 103, 2079-2087.	0.6	55
196	Differential Expression of CD180 and sIgM by B Chronic Lymphocytic Leukaemia Cells (B-CLL) Using Mutated and Unmutated IgVh Genes.. <i>Blood</i> , 2004, 104, 2807-2807.	0.6	1
197	Role of Allogeneic Stem Cell Transplantation in Lymphoplasmacytic Lymphoma. Analysis of 61 Cases from the European Bone Marrow Registry (EBMT).. <i>Blood</i> , 2004, 104, 3326-3326.	0.6	3
198	Patients with Lymphoplasmacytic Lymphoma Can Be Salvaged with Autologous Stem Cell Transplantation, Irrespectively of the Number of Previous Treatment Lines. Analysis of 146 Cases from the European Bone Marrow Transplant Registry (EBMT).. <i>Blood</i> , 2004, 104, 11-11.	0.6	33

#	ARTICLE	IF	CITATIONS
199	Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. <i>Haematologica</i> , 2004, 89, 435-43.	1.7	39
200	Microvasculitic paraproteinaemic polyneuropathy and B-cell lymphoma. <i>Journal of the Peripheral Nervous System</i> , 2003, 8, 100-107.	1.4	10
201	Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 120, 154-165.	1.2	30
202	T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor ly. <i>British Journal of Haematology</i> , 2003, 123, 309-322.	1.2	44
203	Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 257-265.	2.0	89
204	Reconstitution of T-cell repertoire after autologous stem cell transplantation: Influence of CD34 selection and cytomegalovirus infection. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 198-205.	2.0	38
205	High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. <i>Blood</i> , 2002, 99, 4357-4363.	0.6	349
206	Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. <i>Blood</i> , 2002, 99, 1071-1078.	0.6	333
207	Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. <i>Blood</i> , 2002, 100, 3121-3127.	0.6	236
208	Fetal haemopoietic cells display enhanced migration across endothelium. <i>British Journal of Haematology</i> , 2002, 116, 392-400.	1.2	14
209	Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS® (v2Å·1) and Isolex® 300i (v2Å·5) clinical scale devices. <i>British Journal of Haematology</i> , 2002, 118, 117-123.	1.2	38
210	Influence of cell cycling and cell division on transendothelial migration of CD34+ cells. <i>British Journal of Haematology</i> , 2002, 119, 500-509.	1.2	14
211	Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. <i>British Journal of Haematology</i> , 2002, 119, 1125-1132.	1.2	74
212	Transmigration of CD34+ Cells Across Specialized and Nonspecialized Endothelium Requires Prior Activation by Growth Factors and Is Mediated by PECAM-1 (CD31). <i>Blood</i> , 1998, 91, 1196-1205.	0.6	99
213	Selective migration of highly differentiated primed T cells across human umbilical vein endothelial cells. <i>Biochemical Society Transactions</i> , 1997, 25, 258S-258S.	1.6	5
214	Interleukin-3 administration enhances human monocyte function in vivo. <i>British Journal of Haematology</i> , 1994, 88, 515-519.	1.2	8
215	Pentoxifylline at clinically achievable levels inhibits FMLP-induced neutrophil responses, but not priming, upregulation of cell-adhesion molecules, or migration induced by GM-CSF. <i>European Journal of Haematology</i> , 1993, 50, 1-10.	1.1	22
216	The effect of macrophage colony-stimulating factor on haemopoietic recovery after autologous bone marrow transplantation. <i>British Journal of Haematology</i> , 1992, 81, 288-295.	1.2	19

#	ARTICLE	IF	CITATIONS
217	Differential effects of granulocyte and granulocyte macrophage colony stimulating factors (G and Tj ETQq1 1 0.784314 rgB / 1992, 49, 251-259.	1.1	76
218	In vivo effects of macrophage colony-stimulating factor on human monocyte function. British Journal of Haematology, 1991, 77, 25-31.	1.2	59
219	Epidemiology of myeloma. , 0, , 1-10.		0
220	Imaging of myeloma. , 0, , 28-38.		0
221	Cell cycle regulation and myeloma precursor cells. , 0, , 39-47.		0
222	The genetic and epigenetic mechanisms underlying the behavior of myeloma. , 0, , 48-63.		0
223	The myeloma bone marrow environment and survival signaling. , 0, , 64-83.		0
224	Immune dysfunction in multiple myeloma. , 0, , 84-95.		0
225	Myeloma bone disease " pathogenesis of bone destruction and therapeutic strategies. , 0, , 96-109.		0
226	Principles of pathway directed therapy. , 0, , 110-120.		0
227	Multiple myeloma: management of de novo disease to include HDT. , 0, , 134-143.		0
228	Treatment of relapsed/refractory myeloma. , 0, , 144-166.		0
229	Solitary bone and extra-medullary plasmacytoma. , 0, , 167-173.		1
230	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 190-215.		0
231	Treatment of emergent peripheral neuropathy in plasma cell disorders. , 0, , 245-254.		0
232	The management of infection in myeloma. , 0, , 276-287.		0
233	Diagnosis of myeloma and related plasma cell disorders. , 0, , 11-27.		0
234	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. , 0, , 121-133.		2

#	ARTICLE	IF	CITATIONS
235	Castlemanâ€™s disease. , 0, , 216-224.		0
236	POEMS syndrome and paraproteinemic syndromes: management and follow-up. , 0, , 225-244.		0
237	Management of renal failure in multiple myeloma. , 0, , 255-275.		0